Effects of light on metalloporphyrin‐treated newborn mice
暂无分享,去创建一个
[1] D. Stevenson,et al. Effect of light exposure on metalloporphyrin-treated newborn mice , 2012, Pediatric Research.
[2] D. Stevenson,et al. Metalloporphyrins – An Update , 2012, Front. Pharmacol..
[3] D. Stevenson,et al. Effects of Zinc Deuteroporphyrin Bis Glycol on Newborn Mice After Heme Loading , 2011, Pediatric Research.
[4] D. Stevenson,et al. In vitro inhibition of heme oxygenase isoenzymes by metalloporphyrins , 2011, Journal of Perinatology.
[5] K. Cal,et al. Spray drying technique: II. Current applications in pharmaceutical technology. , 2010, Journal of pharmaceutical sciences.
[6] K. Cal,et al. Spray drying technique. I: Hardware and process parameters. , 2010, Journal of pharmaceutical sciences.
[7] M. Eslamian,et al. Recent advances in nanoparticle preparation by spray and micro-emulsion methods. , 2009, Recent patents on nanotechnology.
[8] B. Poindexter,et al. Aggressive vs. conservative phototherapy for infants with extremely low birth weight. , 2008, The New England journal of medicine.
[9] Reinhard Vehring,et al. Pharmaceutical Particle Engineering via Spray Drying , 2007, Pharmaceutical Research.
[10] D. Stevenson,et al. Pharmacology Review: Tin Mesoporphyrin for the Prevention of Severe Neonatal Hyperbilirubinemia , 2007 .
[11] Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. , 2004, Pediatrics.
[12] Hui Zhao,et al. Selection of potential therapeutics based on in vivo spatiotemporal transcription patterns of heme oxygenase-1 , 2002, Journal of Molecular Medicine.
[13] D. Stevenson,et al. Alternative Metalloporphyrins for the Treatment of Neonatal Jaundice , 2001, Journal of Perinatology.
[14] L Yu,et al. Amorphous pharmaceutical solids: preparation, characterization and stabilization. , 2001, Advanced drug delivery reviews.
[15] K. Mäder,et al. Solid lipid nanoparticles: production, characterization and applications. , 2001, Advanced drug delivery reviews.
[16] S J Prestrelski,et al. Biopharmaceutical powders: particle formation and formulation considerations. , 2000, Current pharmaceutical biotechnology.
[17] D. Stevenson,et al. Selective inhibition of heme oxygenase, without inhibition of nitric oxide synthase or soluble guanylyl cyclase, by metalloporphyrins at low concentrations. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[18] C. Hammerman,et al. Bilirubin conjugation, reflected by conjugated bilirubin fractions, in glucose-6-phosphate dehydrogenase-deficient neonates: a determining factor in the pathogenesis of hyperbilirubinemia. , 1998, Pediatrics.
[19] D. Stevenson,et al. Rhesus Isoimmunization: Increased Hemolysis during Early Infancy , 1997, Pediatric Research.
[20] D. Stevenson,et al. Duration of Action and Tissue Distribution of Zinc Protoporphyrin in Neonatal Rats , 1996, Pediatric Research.
[21] D. Stevenson,et al. Characterization of porphyrin heme oxygenase inhibitors. , 1996, Canadian journal of physiology and pharmacology.
[22] H. Schulman,et al. Inhibition of hippocampal heme oxygenase, nitric oxide synthase, and long-term potentiation by metalloporphyrins , 1994, Neuron.
[23] D. Stevenson,et al. Direct Relationship of Fetal Carboxyhemoglobin with Hemolysis in Alloimmunized Pregnancies , 1994, Pediatric Research.
[24] C. Henschke,et al. Control of jaundice in preterm newborns by an inhibitor of bilirubin production: studies with tin-mesoporphyrin. , 1994, Pediatrics.
[25] D. Stevenson,et al. Targeting Zinc Protoporphyrin Liposomes to the Spleen Using Reticuloendothelial Blockade with Blank Liposomes , 1993, Pediatric Research.
[26] A. Kappas,et al. Targeted Delivery of a Heme Oxygenase Inhibitor with a Lyophilized Liposomal Tin Mesoporphyrin Formulation , 1993, Pharmaceutical Research.
[27] D. Stevenson,et al. Selection of Metalloporphyrin Heme Oxygenase Inhibitors Based on Potency and Photoreactivity , 1993, Pediatric Research.
[28] D. Stevenson,et al. Jaundice in healthy, term neonates: do we need new action levels or new approaches? , 1992, Pediatrics.
[29] D. Stevenson,et al. In vitro and in vivo characteristics of a heme oxygenase inhibitor: ZnBG. , 1991, The American journal of the medical sciences.
[30] D. Stevenson,et al. Neonatal hyperbilirubinemia and physical and cognitive performance at 17 years of age. , 1991, Pediatrics.
[31] N. L. Greenbaum,et al. Tin(Sn+4)-diiododeuteroporphyrin; an in vitro and in vivo inhibitor of heme oxygenase with substantially reduced photoactive properties. , 1991, The Journal of pharmacology and experimental therapeutics.
[32] D. Stevenson,et al. Zinc protoporphyrin administration for suppression of increased bilirubin production by iatrogenic hemolysis in rhesus neonates. , 1990, The Journal of pediatrics.
[33] A. Kappas,et al. Targeting of heme oxygenase inhibitors to the spleen markedly increases their ability to diminish bilirubin production. , 1989, Pediatrics.
[34] D. Stevenson,et al. In Vitro Inhibition of Adult Rat Intestinal Heme Oxygenase by Metalloporphyrins , 1989, Pediatric Research.
[35] D. Stevenson,et al. The use of metalloporphyrins for the chemoprevention of neonatal jaundice. , 1989, American journal of diseases of children.
[36] D. Stevenson,et al. Effects of oral administration of tin and zinc protoporphyrin on neonatal and adult rat tissue heme oxygenase activity. , 1988, Journal of pediatric gastroenterology and nutrition.
[37] M. Maines. Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications , 1988, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[38] S. Hintz,et al. Recovery of Exogenous Heme as Carbon Monoxide and Biliary Heme in Adult Rats After Tin Protoporphyrin Treatment , 1987, Journal of pediatric gastroenterology and nutrition.
[39] G. Drummond,et al. Control of heme metabolism with synthetic metalloporphyrins. , 1986, The Journal of clinical investigation.
[40] M. Maines,et al. Prevention of neonatal hyperbilirubinaemia in non-human primates by Zn-protoporphyrin. , 1985, The Biochemical journal.
[41] D. W. Smith,et al. Bilirubin Production After Supplemental Oral Vitamin E Therapy in Preterm Infants , 1985, Journal of pediatric gastroenterology and nutrition.
[42] K. Anderson,et al. Control of Heme Oxygenase and Plasma Levels of Bilirubin by a Synthetic Heme Analogue, Tin‐Protoporphyrin , 1984, Hepatology.
[43] G. Drummond,et al. Prevention of neonatal hyperbilirubinemia by tin protoporphyrin IX, a potent competitive inhibitor of heme oxidation. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[44] V. Hanson,et al. CNS abnormalities after neonatal hemolytic disease or hyperbilirubinemia. A prospective study of 405 patients. , 1969, American journal of diseases of children.
[45] H. Marver,et al. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. , 1968, Proceedings of the National Academy of Sciences of the United States of America.
[46] T. Valaes,et al. Neonatal Jaundice in Glucose - 6 - Phosphate - Dehydrogenase - Deficient Infants , 1962, British medical journal.
[47] D. Stevenson,et al. Glucose-6-phosphate dehydrogenase deficiency and carboxyhemoglobin concentrations associated with bilirubin-related morbidity and death in Nigerian infants. , 1995, The Journal of pediatrics.
[48] D. Stevenson,et al. Role of Lipid Peroxidation in Metalloporphyrin-Mediated Phototoxic Reactions in Neonatal Rats , 1993, Pediatric Research.
[49] H. Vallier,et al. Oral administration of zinc deuteroporphyrin IX 2,4 bis glycol inhibits heme oxygenase in neonatal rats. , 1991, Developmental pharmacology and therapeutics.
[50] H. Vallier,et al. Absorption of zinc deuteroporphyrin IX 2,4-bis-glycol by the neonatal rat small intestine in vivo. , 1991, Developmental pharmacology and therapeutics.
[51] D. Stevenson,et al. Heme catabolism in rhesus neonates inhibited by zinc protoporphyrin. , 1990, Developmental pharmacology and therapeutics.
[52] H. Vreman,et al. Increased carbon monoxide excretion in Bolivian squirrel monkeys with fasting hyperbilirubinemia. , 1990, Journal of medical primatology.
[53] D K Stevenson,et al. Heme oxygenase activity as measured by carbon monoxide production. , 1988, Analytical biochemistry.
[54] M. Maines. Zinc . protoporphyrin is a selective inhibitor of heme oxygenase activity in the neonatal rat. , 1981, Biochimica et biophysica acta.